GlassScriptPhysician profile
Marshall Crespin
NPI 1497125009
$8,217.81
in general payments reported to CMS, 2019-2025
43 companies · $2,733 in 2025
The $2,733 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167 · 2022: $1,243 · 2023: $1,810 · 2024: $2,265 · 2025: $2,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,807.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,985.84 | 2021-2025 | |
| Ucb, INC. | $603.04 | 2022-2025 | Briviact, Rystiggo, Fintepla |
| Celgene Corporation | $463.38 | 2023-2025 | Zeposia |
| Lundbeck LLC | $400.80 | 2022-2025 | Vyepti, Rexulti |
| Biogen, INC. | $372.47 | 2021-2025 | Tysabri, Vumerity |
| Pfizer INC. | $308.99 | 2023-2025 | |
| Sk Life Science, INC. | $299.09 | 2022-2025 | |
| Eisai INC. | $297.99 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $271.94 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $264.76 | 2022-2025 | Crexont, Rytary, Lyvispah |
| Lilly USA, LLC | $253.26 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Argenx US, INC. | $214.54 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $197.60 | 2022-2025 | Ultomiris |
| Amgen INC. | $173.28 | 2022-2025 | Aimovig, Uplizna |
| Merz Pharmaceuticals, LLC | $145.13 | 2024-2025 | Xeomin, Inbrija |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $143.24 | 2022 | |
| Neurelis, INC. | $131.84 | 2022-2025 | Valtoco |
| Tg Therapeutics, INC. | $129.70 | 2023-2025 | |
| Emd Serono, INC. | $125.62 | 2022-2025 | Mavenclad |
| Jazz Pharmaceuticals INC. | $123.25 | 2022-2025 | |
| Genentech USA, INC. | $120.87 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Mdd US Operations, LLC | $112.01 | 2022-2025 | Gocovri |
| Livanova USA, INC. | $94.52 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Mallinckrodt Hospital Products INC. | $87.72 | 2024-2025 | Acthar |
| Csl Behring | $82.88 | 2022-2025 | Hizentra |
| Ani Pharmaceuticals, INC. | $80.96 | 2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $80.36 | 2024-2025 | Wainua |
| Sumitomo Pharma America, INC. | $76.59 | 2023-2024 | Aptiom |
| Otsuka America Pharmaceutical, INC. | $71.32 | 2023-2025 | Rexulti, Nuedexta |
| Kyowa Kirin, INC. | $68.79 | 2022-2024 | Nourianz |
| E.R. Squibb & Sons, L.L.C. | $65.33 | 2023-2024 | Zeposia |
| Acorda Therapeutics, INC | $64.84 | 2022-2023 | Inbrija, Ampyra |
| Neurocrine Biosciences, INC. | $59.22 | 2022-2025 | |
| Allergan, INC. | $38.70 | 2021 | |
| Impel Pharmaceuticals INC. | $35.17 | 2022-2023 | Trudhesa |
| Medtronic, INC. | $34.41 | 2022 | |
| Supernus Pharmaceuticals, INC. | $23.49 | 2025 | Qelbree |
| Springworks Therapeutics, INC. | $22.53 | 2025 | Gomekli |
| Teva Pharmaceuticals USA, INC. | $22.47 | 2025 | Austedo Xr |
| Alnylam Pharmaceuticals INC. | $21.97 | 2025 | Onpattro |
| Avion Pharmaceuticals | $19.87 | 2022 | |
| Corium, LLC | $14.33 | 2023 | Adlarity |
| Genzyme Corporation | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Crespin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.